(Q53577661)

English

Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.

scientific article published in March 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

Cytomegalovirus

0 references

cytomegaloviral disease

1 reference

based on heuristic

inferred from title

author name string

M Battiwalla

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

P Paplham

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

N G Almyroudis

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

A McCarthy

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

A Abdelhalim

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

A Elefante

6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

P Smith

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

J Becker

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

P L McCarthy

9

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

B H Segal

10

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

Transplant Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

9

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

28-32

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00170.X

21 January 2018

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00170.X

21 January 2018

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00170.X

21 January 2018

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00170.X

21 January 2018

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00170.X

21 January 2018

Leflunomide therapy for cytomegalovirus disease in renal allograft recepients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00170.X

21 January 2018

Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00170.X

21 January 2018

Identifiers

10.1111/J.1399-3062.2006.00170.X

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17313468

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53577661&oldid=1629805870"